Palovarotene
Sohonos (palovarotene) is a small molecule pharmaceutical. Palovarotene was first approved as Sohonos on 2023-08-16. It is used to treat heterotopic ossification in the USA. The pharmaceutical is active against retinoic acid receptor gamma.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Sohonos
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| sohonos | New Drug Application | 2023-08-24 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| heterotopic ossification | — | D009999 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
PALOVAROTENE, SOHONOS, IPSEN | |||
| 2030-08-16 | ODE-439 | ||
| 2028-08-16 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myositis ossificans | D009221 | — | M61.1 | 1 | 3 | 2 | — | 2 | 8 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple hereditary exostoses | D005097 | — | Q78.6 | — | 1 | — | — | — | 1 |
| Exostoses | D005096 | — | M27.8 | — | 1 | — | — | — | 1 |
| Osteophyte | D054850 | — | M25.7 | — | 1 | — | — | — | 1 |
| Osteochondroma | D015831 | — | — | — | 1 | — | — | — | 1 |
| Osteochondromatosis | D018216 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dry eye syndromes | D015352 | — | H04.12 | 1 | — | — | — | — | 1 |
| Eye diseases | D005128 | EFO_0003966 | H44 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Palovarotene |
| INN | palovarotene |
| Description | Palovarotene is a stilbenoid. |
| Classification | Small molecule |
| Drug class | arotinoid derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(/C=C/c3ccc(C(=O)O)cc3)cc21 |
Identifiers
| PDB | — |
| CAS-ID | 410528-02-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2105648 |
| ChEBI ID | — |
| PubChem CID | 10295295 |
| DrugBank | DB05467 |
| UNII ID | 28K6I5M16G (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 406 documents
View more details
Safety
Black-box Warning
Black-box warning for: Sohonos
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use